Education
About Us
Working with TipRanks
Follow Us
Unicycive Therapeutics (UNCY)
NASDAQ:UNCY
RESEARCH TOOLSreports
UNCY Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.20 - $1.60
Previous CloseN/A
Volume1.16M
Average Volume (3M)886.56K
Market Cap
$70.58M
Enterprise Value$4.74M
Total Cash (Recent Filing)-$25.00K
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.97
Next Earnings
Mar 27, 2025EPS Estimate
-0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.80
Shares Outstanding103,796,410
10 Day Avg. Volume756,030
30 Day Avg. Volume886,560
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)114.16
Price to Cash Flow (P/CF)-2.10
P/FCF Ratio0.00
Enterprise Value/Market Cap0.07
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit7.02
Enterprise Value/Ebitda-0.12
Forecast
1Y Price Target
$5.50Price Target Upside708.82% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
Bulls Say, Bears Say
Bulls Say
Market OpportunityUnder TDAPA, new therapies like OLC can enter at significantly increased pricing versus the competition, providing a competitive advantage.
Product DifferentiationOLC's small pill size and ability to be taken without chewing are two differentiating attributes that make it an attractive treatment option among phosphate binders.
Regulatory ApprovalThe NDA for OLC was accepted for review by FDA with a PDUFA date, presenting a significant opportunity for Unicycive.
Bears Say
Commercialization ChallengesRisks also include failure to secure a commercialization partner or sufficient capital to market products independently.
Market CompetitionA smaller than anticipated commercial opportunity due to market size, competition, and pricing is a potential risk to the target price.
Regulatory ChallengesRisks include failure to secure regulatory approvals for OLC or UNI-494.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
UNCY FAQ
What was Unicycive Therapeutics’s price range in the past 12 months?
Unicycive Therapeutics lowest stock price was $0.20 and its highest was $1.60 in the past 12 months.
What is Unicycive Therapeutics’s market cap?
Unicycive Therapeutics’s market cap is $70.58M.
When is Unicycive Therapeutics’s upcoming earnings report date?
Unicycive Therapeutics’s upcoming earnings report date is Mar 27, 2025 which is in 3 days.
How were Unicycive Therapeutics’s earnings last quarter?
Unicycive Therapeutics released its earnings results on Nov 13, 2024. The company reported -$0.05 earnings per share for the quarter, beating the consensus estimate of -$0.154 by $0.104.
Is Unicycive Therapeutics overvalued?
According to Wall Street analysts Unicycive Therapeutics’s price is currently Undervalued.
Does Unicycive Therapeutics pay dividends?
Unicycive Therapeutics does not currently pay dividends.
What is Unicycive Therapeutics’s EPS estimate?
Unicycive Therapeutics’s EPS estimate is -0.09.
How many shares outstanding does Unicycive Therapeutics have?
Unicycive Therapeutics has 103,796,410 shares outstanding.
What happened to Unicycive Therapeutics’s price movement after its last earnings report?
Unicycive Therapeutics reported an EPS of -$0.05 in its last earnings report, beating expectations of -$0.154. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Unicycive Therapeutics?
Among the largest hedge funds holding Unicycive Therapeutics’s share is RA Capital Management. It holds Unicycive Therapeutics’s shares valued at 0.
---
Unicycive Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.50 (708.82% Upside)
$5.50 (708.82% Upside)
Hedge Fund Trend
Decreased
By 2.6M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.4%
Last 30 Days ▼ 10.4%
Last 30 Days ▼ 10.4%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-48.87%
12-Months-Change
Fundamentals
Return on Equity
-185.19%
Trailing 12-Months
Asset Growth
98.41%
Trailing 12-Months
Company Description
Unicycive Therapeutics
Unicycive Therapeutics Inc is a biotechnology company dedicated towards developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's lead drug, Renazorb, is a novel phosphate binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury.
---
UNCY Stock 12 Month Forecast
Average Price Target
$5.50
▲(708.82% Upside)
Technical Analysis
Alkermes
―
BioCryst
―
Corbus Pharmaceuticals
―
Akari Therapeutics
―
Atea Pharmaceuticals
―
Best Analysts Covering UNCY
1 Year
1 Year Success Rate
6/9 ratings generated profit
1 Year Average Return
+23.80%
reiterated a buy rating last month
Copying Robert LeBoyer's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +23.80% per trade.
---